SAB Biotherapeutics Says SAB-142 Receives FDA Fast Track Designation in Type 1 Diabetes

09:17 AM EDT, 10/13/2026 (MT Newswires) -- SAB Biotherapeutics (SABS) said Tuesday that the US Food and Drug Administration has granted fast track designation for SAB-142 in stage 3 type 1 diabetes. The designation is intended to expedite the review of potential therapies for serious conditions that fill an unmet medical need, and help get important new drugs to patients faster, according to a statement. The company said it expects to complete enrollment in Q4 for a phase 2b trial of SAB-142 in patients within 100 days of a stage 3 type 1 diabetes diagnosis, with topline data anticipated in H2 of 2027. Shares of SAB Biotherapeutics were up 6% pre-bell Tuesday.